Global Musculoskeletal Partnering Deals and Agreements 2012-2018

Dublin, March 15, 2018 -- The "Global Musculoskeletal Partnering 2012-2018: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.

Global Musculoskeletal Partnering 2012 to 2018 provides the full collection of Musculoskeletal disease deals signed between the world's pharmaceutical and biotechnology companies since 2012.

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Musculoskeletal disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Musculoskeletal deals.

The report presents financial deal terms values for Musculoskeletal deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

In addition, a comprehensive appendix is provided with each report of all Musculoskeletal partnering deals signed and announced since 2012. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Musculoskeletal partnering and dealmaking since 2012.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Musculoskeletal technologies and products.

Report scope

Global Musculoskeletal Partnering 2012 to 2018 includes:

• Trends in Musculoskeletal dealmaking in the biopharma industry since 2012
• Analysis of Musculoskeletal deal structure
• Access to headline, upfront, milestone and royalty data
• Access to hundreds of Musculoskeletal deal contract documents
• Comprehensive access to over 3500 Musculoskeletal deal records
• The leading Musculoskeletal deals by value since 2012
• Most active Musculoskeletal dealmakers since 2012

The report includes deals for the following indications: Arthritis, Ankylosing spondylitis, Juvenile arthritis, Osteoarthritis, Psoriatic arthriti, Rheumatoid arthritis, Bone fracture, Hip, Carpel tunnel syndrome, Frozen shoulder, Gout, Knee, Meniscus damage, Muscular dystrophy, Osteoporosis, Paget's disease, Spinal muscular atrophy, Bone pain, Back pain, Muscular pain, Stiffness, Weakness, plus other musculoskeletal indications.

In Global Musculoskeletal Partnering 2012 to 2018, available deals and contracts are listed by:

• Headline value
• Upfront payment value
• Royalty rate value
• Stage of development at signing
• Deal component type
• Technology type
• Specific therapy indication
  

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Musculoskeletal dealmaking

2.1. Introduction
2.2. Musculoskeletal partnering over the years
2.3. Musculoskeletal partnering by deal type
2.4. Musculoskeletal partnering by industry sector
2.5. Musculoskeletal partnering by stage of development
2.6. Musculoskeletal partnering by technology type
2.7. Musculoskeletal partnering by therapeutic indication

Chapter 3 - Financial deal terms for Musculoskeletal partnering

3.1. Introduction
3.2. Disclosed financials terms for Musculoskeletal partnering
3.3. Musculoskeletal partnering headline values
3.4. Musculoskeletal deal upfront payments
3.5. Musculoskeletal deal milestone payments
3.6. Musculoskeletal royalty rates

Chapter 4 - Leading Musculoskeletal deals and dealmakers

4.1. Introduction
4.2. Most active in Musculoskeletal partnering
4.3. List of most active dealmakers in Musculoskeletal
4.4. Top Musculoskeletal deals by value

Chapter 5 - Musculoskeletal contract document directory

5.1. Introduction
5.2. Musculoskeletal partnering deals where contract document available

Chapter 6 - Musculoskeletal dealmaking by therapeutic target

6.1. Introduction
6.2. Deals by Musculoskeletal therapeutic target

For more information about this report visit https://www.researchandmarkets.com/research/bmxjsr/global?w=12

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Manager
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         Related Topics: Musculoskeletal Disorders Drugs